The stock last traded at $0.50 which is well below $0.58, the 50 day moving average and quite a bit lower than the 200 day moving average of $0.65. The 50 day moving average was down by -14.212% whereas the 200 day moving average was down $-0.15 or -22.689%. (NASDAQ:CTRV) shares saw light trading volume with 899K shares changing hands on Tuesday. Overall, volume was down 55.23% under the stocks normal daily volume.
Investors are more bullish on ContraVir Pharmaceuticals Inc if you watch the fall in short interest. The firm had a fall in short interest of -4.35% between September 29, 2017 and October 13, 2017. Short shares decreased from 3,707,842 to 3,546,436 over that period. Days to cover decreased -5.0 to 1.0 and the short interest percentage is 0.06% as of October 13.
A few notable investment firms have updated their holdings. Cambridge Investment Research Advisors, Inc. divested its holdings by shedding 1,970 shares a decrease of 11.7%. Cambridge Investment Research Advisors, Inc. controls 14,870 shares valued at $9,000. The value of the position overall is down by 70.0%. As of the end of the quarter Creative Planning had disposed of 557 shares trimming its position 31.5%. The value of the investment in (CTRV) decreased from $3,000 to $1,000 a change of $2,000 quarter over quarter.
As of quarter end Prospera Financial Services Inc had bought a total of 500 shares growing its stake by 0.3%. The value of the investment in CTRV went from $99,000 to $126,000 increasing 27.3% for the reporting period. Bank Of Montreal /can/ reduced its position by selling 30,000 shares a decrease of 37.5% as of 09/30/2017. Bank Of Montreal /can/ currently owns 50,000 shares worth $26,000. The total value of its holdings decreased 43.5%.
In the latest earnings report the EPS was $-0.30 and is projected to be $-0.37 for the current year with 78,001,000 shares presently outstanding. Next quarter’s EPS is estimated at $-0.08 with next year’s EPS projected to be $-0.37.
ContraVir Pharmaceuticals, Inc., launched on May 15, 2013, is a biopharmaceutical company. The Company focuses on the development of antiviral drugs for the treatment of Hepatitis B virus (HBV) infections. The Company develops a range of compounds to treat HBV infection, which include CMX157 and CRV431. The Company is also developing an antiviral asset, FV-100..